Biomerica (BMRA) Receives a Buy from B.Riley FBR

By Jason Carr

In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Biomerica (BMRAResearch Report), with a price target of $6.25. The company’s shares closed last Monday at $2.97.

According to TipRanks.com, D’silva is a 3-star analyst with an average return of 2.6% and a 41.0% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals, EyePoint Pharmaceuticals, and Eton Pharmaceuticals.

Biomerica has an analyst consensus of Moderate Buy, with a price target consensus of $6.25.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.69 and a one-year low of $2.15. Currently, Biomerica has an average volume of 19.63K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests.